Ask VialBase
other

Livagen

Also known as: Lys-Glu-Asp-Ala, KEDA peptide
Preliminary evidence FDA: Not FDA-approved WADA: Not listed

Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, "KEDA") from the Khavinson bioregulator family, classed as a liver "Cytogen." It is studied as an epigenetic regulator that activates chromatin and shifts tissue-specific gene expression, with reported effects on hepatic and gastrointestinal enzyme activity. Evidence is mostly in vitro and Russian-language clinical; it is not FDA-approved. For educational purposes only. Not medical advice. Livagen is the tetrapeptide Lys-Glu-Asp-Ala (KEDA). Like the other Cytogens, its proposed action is epigenetic rather than receptor-mediated: 1. Chromatin activation. A human study reported that Livagen decondenses (activates) heterochromatin in lymphocytes from elderly subjects, reversing an age-related loss of

This content is for educational and research purposes only. VialBase does not provide medical advice. Consult a healthcare professional before using any peptide.

Molecular weight 461.5 Da
Half-life ~minutes estimated;
CAS number —
Route Subcutaneous · Oral subcutaneous preferred
02

Mechanism

Synthetic tetrapeptide (Lys-Glu-Asp-Ala) classed as a liver "Cytogen" bioregulator. Proposed to act epigenetically — decondensing/activating chromatin and shifting tissue-specific gene expression — with reported effects on hepatic and gastrointestinal enzyme activity and on lymphocyte chromatin in aged subjects. Evidence is largely in vitro and Russian-language clinical, not FDA-grade.

03

Dosing

DOSE RANGE 10–20 mg per cycle
FREQUENCY 1×/day
CYCLE LENGTH 10–20 days, repeated up to 4×/year

Short pulsed Khavinson-style cycles. Used in liver-support and detoxification protocols; subcutaneous and oral routes are both described, with no published bioavailability data.

04

Research summary

Study Type Year Key Finding
Effects of Livagen peptide on chromatin activation in lymphocytes from old people In vitro (human lymphocytes) 2002 Livagen decondensed (activated) heterochromatin in lymphocytes from elderly subjects
Effect of the peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum In vitro (human serum) 2003 Livagen (with Epitalon) influenced enkephalin-degrading enzyme activity in human serum
Effect of peptide Livagen on activity of digestive enzymes in the gastrointestinal tract Animal (gastrointestinal) 2005 Livagen altered activity of digestive enzymes in the gastrointestinal tract
05

Stacking & interactions

Comprehensive gut–liver healing

Organ-detox / tissue-repair protocols

Longevity stack — hepatic + pineal/telomere axes

06

Sourcing

Current prices

Updated today

20mg

Size unspecified

Only vendor stocking this size on the VialBase roster.

Stocks this compound Third-party tested Public COAs Positive rep

Save 15% with code VIALBASE at checkout

Stocks this compound Third-party tested Public COAs

Save 15% with code vialbase15 at checkout

Stocks this compound Third-party tested Public COAs

VialBase may earn a commission on purchases through partner links — never at additional cost to you. Full disclosure.

What bloodwork do I need?

Reference ranges are general guidelines. Consult your physician for interpretation.

PRE-CYCLE
  • CMP
  • CBC
DURING CYCLE
  • CMP
POST-CYCLE
  • CMP
  • CBC
Safety & Regulatory Status
FDA STATUS Not FDA-approved
WADA STATUS Not listed

Regulatory status for Livagen may change. Verify current status with your jurisdiction before use. This is not legal or medical advice.

Frequently Asked Questions

What is Livagen?
Livagen is a synthetic tetrapeptide (Lys-Glu-Asp-Ala, "KEDA") from the Khavinson short-peptide bioregulator family. It is classed as a liver "Cytogen" and is studied for hepatic support and as an epigenetic regulator of chromatin and tissue-specific gene expression.
What does the research on Livagen show?
A named human study reported that Livagen activates (decondenses) chromatin in lymphocytes from older subjects, and animal work found effects on digestive-enzyme activity in the gastrointestinal tract. These are small, mostly Russian-language studies; there are no FDA-registered clinical trials, so the evidence tier is preliminary.
What is Livagen's peptide sequence?
Livagen is the tetrapeptide Lys-Glu-Asp-Ala (KEDA), molecular weight ≈462 Da. It is structurally related to the other Khavinson Cytogens (Vilon, Vesugen, Epithalon).
How is Livagen dosed?
Practitioner protocols use short pulsed courses of about 10–20 mg per cycle for 10–20 days, repeated up to four times a year, subcutaneously or orally. These are traditional Khavinson regimens, not trial-validated doses.
Is Livagen FDA-approved or safe for the liver?
Livagen is not FDA-approved and is sold only as a research chemical. While it is marketed for liver support and is generally reported as well tolerated, controlled human safety and efficacy data do not exist. Anyone with liver disease should be managed by a physician rather than relying on an unproven peptide.

References

  1. Khavinson VKh et al.. Effects of Livagen peptide on chromatin activation in lymphocytes from old people. Bull Exp Biol Med (2002). PMID: 12533768
  2. Kost NV et al.. Effect of the peptide bioregulators livagen and epitalon on enkephalin-degrading enzymes in human serum. Izv Akad Nauk Ser Biol (2003). PMID: 12942748
  3. Timofeeva NM et al.. Effect of peptide Livagen on activity of digestive enzymes in the gastrointestinal tract. Adv Gerontol (2005). PMID: 16075683